Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Lymphocytosis (lymphocytes > 4 G/L in adults)

Haematology · Abnormal laboratory result · updated 2026-11-08

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: Monoclonal B lymphocytosis in 17% of adults aged 40 or over screened by cytometry in a US cohort [1]

Lymphocytosis in adults: first tests and recheck

Laboratory tests

In 3 months

Detailed explanation and international comparison (in French): read it in English (machine translation)

Persistent lymphocytosis (> 3 months) without reactive cause

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Stage A CLL or monoclonal B lymphocytosis: monitoring in the community

Every 6 to 12 months (depending on progression)

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Warning signs: urgent advice

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (14)
  1. Ryan CE, Ahn IE, Sekar A, et al. State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee. Blood Cancer J. 2025;15(1):148.
  2. NHS Lothian. RefHelp : Lymphocytosis (haematology referral guideline), version du 24 juillet 2026.
  3. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1103 (phénotypage des cellules anormales), 1104 (hémogramme) et 1260 (cytomégalovirus, IgG et IgM).
  4. Carbonetti NH. Pertussis leukocytosis: mechanisms, clinical relevance and treatment. Pathog Dis. 2016;74(7):ftw087.
  5. Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Med. 2018;15(11):e1002685.
  6. Institut national du cancer. Leucémie lymphoïde chronique : du diagnostic au suivi. Collection Outils pour la pratique des médecins généralistes. Boulogne-Billancourt : INCa ; 2023 (expertise adoptée par décision n° 2023-16 du 05/06/2023).
  7. Régent A, Kluger N, Bérezné A, Lassoued K, Mouthon L. Démarche diagnostique devant une lymphopénie : quand penser à la lymphopénie CD4 idiopathique ? Rev Med Interne. 2012;33(11):628-634.
  8. Humber and North Yorkshire Policy and Pathway Repository (York). Lymphocytosis pathway. York and Scarborough Teaching Hospitals, équipe d'hématologie ; créé le 18 juin 2025, modifié le 16 septembre 2025 (révision prévue le 31 mars 2027).
  9. Riley LK, Rupert J. Evaluation of Patients with Leukocytosis. Am Fam Physician. 2015;92(11):1004-1011.
  10. Haute Autorité de santé, Institut national du cancer. Actes et prestations — ALD n° 30 « Leucémie lymphoïde chronique ». Octobre 2012.
  11. Wendtner CM, Al-Sawaf O, Binder M, Dreger P, et al. Chronische Lymphatische Leukämie (CLL). Leitlinie Onkopedia (DGHO), octobre 2026.
  12. Kreuzer KA, Brüggemann M, Egle A, Gregor M, et al. Monoklonale B-Zell Lymphozytose. Leitlinie Onkopedia (DGHO), août 2024.
  13. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NG12). Mise à jour du 15 avril 2026 : recommandations 1.10.2 et 1.10.3.
  14. Labe P, Meunier A, Leroux P, et al. Variability in the Diagnostic Criteria for Severe Pertussis: A Systematic Review. JAMA Netw Open. 2026;9(7):e2622211.